Tianjin Chase Sun Pharmaceutical (300026) Fundamentals 2026 — P/E 402.4x, Revenue Analysis | SniperIQ
Tianjin Chase Sun Pharmaceutical (300026) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥10.0B, trading at ¥3.34 on the SHZ. This SniperIQ fundamentals page covers Tianjin Chase Sun Pharmaceutical's valuation (P/E 402.4x, P/B 1.3x), profitability (net margin 0.5%), revenue (¥4.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tianjin Chase Sun Pharmaceutical's market cap?
Tianjin Chase Sun Pharmaceutical (300026) has a market capitalization of approximately ¥10.0B, trading at ¥3.34 on the SHZ. Market cap moves with the live share price.
What is Tianjin Chase Sun Pharmaceutical's P/E ratio?
Tianjin Chase Sun Pharmaceutical's trailing twelve-month P/E ratio is 402.4x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tianjin Chase Sun Pharmaceutical?
Tianjin Chase Sun Pharmaceutical runs a net profit margin of 0.5%, a gross margin of 59.0%, and an operating margin of 3.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tianjin Chase Sun Pharmaceutical generate?
Tianjin Chase Sun Pharmaceutical reported revenue of ¥4.9B for fiscal year 2025, with net income of ¥18M and earnings per share (EPS) of 0.0062. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tianjin Chase Sun Pharmaceutical pay a dividend?
Tianjin Chase Sun Pharmaceutical offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Tianjin Chase Sun Pharmaceutical financially healthy?
Tianjin Chase Sun Pharmaceutical carries a debt-to-equity ratio of 0.06x and a current ratio of 4.70x, with a market beta of 0.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tianjin Chase Sun Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tianjin Chase Sun Pharmaceutical (300026) the key facts are: market cap ¥10.0B, P/E 402.4x, revenue ¥4.9B, 52-week range 2.82-4.49. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tianjin Chase Sun Pharmaceutical's full fundamentals live
Get Tianjin Chase Sun Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.